AXQ Capital LP Buys Shares of 13,757 Gilead Sciences, Inc. $GILD

AXQ Capital LP bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 13,757 shares of the biopharmaceutical company’s stock, valued at approximately $1,527,000. Gilead Sciences makes up 0.6% of AXQ Capital LP’s portfolio, making the stock its 13th biggest holding.

Other large investors have also recently made changes to their positions in the company. Csenge Advisory Group boosted its holdings in shares of Gilead Sciences by 319.0% during the 3rd quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after purchasing an additional 16,288 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its stake in Gilead Sciences by 52.1% during the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock worth $8,713,000 after buying an additional 26,882 shares during the last quarter. Cookson Peirce & Co. Inc. grew its holdings in Gilead Sciences by 249.1% in the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock valued at $1,115,000 after buying an additional 7,168 shares in the last quarter. Railway Pension Investments Ltd grew its holdings in Gilead Sciences by 3.1% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock valued at $157,139,000 after buying an additional 42,200 shares in the last quarter. Finally, TriaGen Wealth Management LLC acquired a new stake in shares of Gilead Sciences in the 3rd quarter worth $1,274,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the transaction, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at $18,709,027.93. The trade was a 1.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $125.08, for a total value of $625,400.00. Following the completion of the sale, the director directly owned 8,920 shares in the company, valued at $1,115,713.60. This represents a 35.92% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 319,891 shares of company stock valued at $45,091,556. 0.27% of the stock is currently owned by company insiders.

Analyst Ratings Changes

GILD has been the subject of several recent analyst reports. The Goldman Sachs Group raised their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research report on Thursday, January 8th. Truist Financial increased their price target on shares of Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $160.00 price target on shares of Gilead Sciences in a research report on Wednesday, February 11th. Wolfe Research upped their price objective on Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a report on Thursday, February 12th. Finally, Mizuho raised their target price on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 18th. Twenty-three investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average target price of $155.44.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $149.83 on Tuesday. The stock has a market capitalization of $185.89 billion, a price-to-earnings ratio of 22.13, a price-to-earnings-growth ratio of 2.01 and a beta of 0.36. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.68 and a quick ratio of 1.31. The business has a 50-day moving average of $134.07 and a 200 day moving average of $124.08. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be paid a $0.82 dividend. The ex-dividend date is Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. Gilead Sciences’s payout ratio is 46.68%.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx in a deal valued at about $7.8B (cash $115/share + $5 CVR), giving Gilead full control of Anito‑cel, a next‑generation CAR‑T for multiple myeloma that could reach regulators this year — a clear strategic boost to Gilead’s oncology franchise. Gilead Sciences to Acquire Arcellx
• Positive Sentiment: Sell‑side support: Needham reaffirmed a “buy” on GILD with a $170 price target, highlighting upside based on pipeline and M&A execution, which provides analyst backing for the medium‑term thesis. Analyst Reaffirmation (Benzinga)
• Neutral Sentiment: Gilead scheduled several investor‑conference presentations (TD Cowen, Leerink, Barclays) in early March — useful for management to frame the Arcellx rationale and provide pipeline / guidance color. Gilead to Present at Upcoming Investor Conferences
• Neutral Sentiment: Health‑care sector dynamics and a mixed broader market (including a late‑day drop in the Dow) are a moderating force — sector strength earlier in the session partly offset by broader risk‑off moves. Sector Update (Yahoo Finance)
• Negative Sentiment: A law firm (Kahn Swick & Foti) is investigating the Arcellx sale for adequacy of price and process, which raises the risk of litigation or a proxy fight that could complicate closing or create management distraction. Arcellx Investor Alert (BusinessWire)
• Negative Sentiment: Market concern about the premium and $7.8B price tag (deal cited as ~68–80% premium) is weighing on Gilead — investors are parsing near‑term cash/valuation impact, integration risk and whether the price fairly reflects risk for an outpatient oncology program. Deal Coverage (Reuters)

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.